MedsFacts Meta-Analysis covering adverse side effect reports of TEBETANE COMPUESTO patients who developed EXTRAPYRAMIDAL DISORDER.
Introduction: MedsFacts provides MD-approved analysis to help both patients and physicians accurately research and assess the risk-reward trade off for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration, social media, and MedsFacts user submissions. Between January 2004 and October 2012, 1 individuals taking TEBETANE COMPUESTO reported EXTRAPYRAMIDAL DISORDER to the FDA. A total of 13 TEBETANE COMPUESTO drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.
Topics covered: This page is designed to help you determine the relationship, if any, between TEBETANE COMPUESTO and EXTRAPYRAMIDAL DISORDER. In doing so, we compare TEBETANE COMPUESTO with other drugs that cause EXTRAPYRAMIDAL DISORDER, to help you evaluate whether or not TEBETANE COMPUESTO causes EXTRAPYRAMIDAL DISORDER. Likewise, this page shows the most highly-reported side effects of TEBETANE COMPUESTO, so you can see if EXTRAPYRAMIDAL DISORDER ranks among TEBETANE COMPUESTO's most well-known side effects.
The Dashboard explained: The Dashboard first shows general Summary Statistics for TEBETANE COMPUESTO and EXTRAPYRAMIDAL DISORDER, such as the raw number and percentage of patients in FDA reports who used TEBETANE COMPUESTO and developed EXTRAPYRAMIDAL DISORDER. Next, the Dashboard lists the most common reasons (indications) why TEBETANE COMPUESTO was prescribed for patients. We then display a pie-chart which shows, in aggregate, what we believe represents general physician opinion of the safety of TEBETANE COMPUESTO. This pie-chart summarizes, for all FDA reports covering TEBETANE COMPUESTO, whether or not the treating physician felt TEBETANE COMPUESTO (versus other drugs the patient was taking) was responsible for the adverse side-effects. After the pie-chart, we itemize the most common side effects in FDA studies covering TEBETANE COMPUESTO. You may click on any of these side effects to learn more about them, in general, or specifically for TEBETANE COMPUESTO. Finally, we identify the drugs most widely associated with TEBETANE COMPUESTO in FDA literature. You may also click on any of these drugs to view it's dashboard.
Reports of TEBETANE COMPUESTO causing EXTRAPYRAMIDAL DISORDER: 1
Reports of any side effect of TEBETANE COMPUESTO : 13
Percentage of TEBETANE COMPUESTO patients where EXTRAPYRAMIDAL DISORDER is a reported side effect: 7.6923076923077%
FDA reports of any drug causing EXTRAPYRAMIDAL DISORDER : 18150
Average percentage for all medicated patients where EXTRAPYRAMIDAL DISORDER is reported as a complication: 0.11375348585493%
Most frequent diagnoses/indications for prescribing TEBETANE COMPUESTO:
PROSTATISM ( 4 patients )
BENIGN PROSTATIC HYPERPLASIA ( 2 patients )
DRUG USE FOR UNKNOWN INDICATION ( 1 patients )
( 0 patients )
Physician opinion on TEBETANE COMPUESTO as adverse event culprit:
Most common side effects for patients taking TEBETANE COMPUESTO:
WEIGHT DECREASED (4 patients)
PROSTATE CANCER (4 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (3 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (3 patients)
CHOLESTATIC LIVER INJURY (3 patients)
ALANINE AMINOTRANSFERASE INCREASED (3 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (3 patients)
BILIRUBIN CONJUGATED INCREASED (3 patients)
DECREASED APPETITE (2 patients)
NAUSEA (2 patients)
Twitter feed for TEBETANE COMPUESTO - Pending/Beta
Drugs with high reportage of EXTRAPYRAMIDAL DISORDER:
METOCLOPRAMIDE (19661 patients)
REGLAN (4979 patients)
RISPERDAL (925 patients)
SEROQUEL (649 patients)
METOCLOPRAMIDE HYDROCHLORIDE (644 patients)
HALOPERIDOL (619 patients)
ABILIFY (453 patients)
RISPERIDONE (416 patients)
ZYPREXA (390 patients)
GEODON (285 patients)
Basic reports are available, free of charge, in PDF format and are suitable for scientific publication. Further data and analytics are available upon request. We are in the process of adding new features to our site, including Q&A interface for patients to speak with experts on medication. Check back with us again in the near future to see.